BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 22495394)

  • 1. Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanoma.
    Tarhini AA; Leng S; Moschos SJ; Yin Y; Sander C; Lin Y; Gooding WE; Kirkwood JM
    J Immunother; 2012 May; 35(4):359-66. PubMed ID: 22495394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma.
    Weber J; Sondak VK; Scotland R; Phillip R; Wang F; Rubio V; Stuge TB; Groshen SG; Gee C; Jeffery GG; Sian S; Lee PP
    Cancer; 2003 Jan; 97(1):186-200. PubMed ID: 12491520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pilot study of granulocyte-macrophage colony-stimulating factor and interleukin-2 as immune adjuvants for a melanoma peptide vaccine.
    Block MS; Suman VJ; Nevala WK; Kottschade LA; Creagan ET; Kaur JS; Quevedo JF; McWilliams RR; Markovic SN
    Melanoma Res; 2011 Oct; 21(5):438-45. PubMed ID: 21697748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization.
    Markovic SN; Suman VJ; Ingle JN; Kaur JS; Pitot HC; Loprinzi CL; Rao RD; Creagan ET; Pittelkow MR; Allred JB; Nevala WK; Celis E
    Am J Clin Oncol; 2006 Aug; 29(4):352-60. PubMed ID: 16891861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I trial of SD-9427 (progenipoietin) with a multipeptide vaccine for resected metastatic melanoma.
    Pullarkat V; Lee PP; Scotland R; Rubio V; Groshen S; Gee C; Lau R; Snively J; Sian S; Woulfe SL; Wolfe RA; Weber JS
    Clin Cancer Res; 2003 Apr; 9(4):1301-12. PubMed ID: 12684398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants.
    Schaed SG; Klimek VM; Panageas KS; Musselli CM; Butterworth L; Hwu WJ; Livingston PO; Williams L; Lewis JJ; Houghton AN; Chapman PB
    Clin Cancer Res; 2002 May; 8(5):967-72. PubMed ID: 12006508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of granulocyte-macrophage colony-stimulating factor and foreign helper protein as immunologic adjuvants on the T-cell response to vaccination with tyrosinase peptides.
    Scheibenbogen C; Schadendorf D; Bechrakis NE; Nagorsen D; Hofmann U; Servetopoulou F; Letsch A; Philipp A; Foerster MH; Schmittel A; Thiel E; Keilholz U
    Int J Cancer; 2003 Mar; 104(2):188-94. PubMed ID: 12569574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Individualized synthetic peptide vaccines with GM-CSF in locally advanced melanoma patients.
    Atzpodien J; Fluck M; Reitz M
    Cancer Biother Radiopharm; 2004 Dec; 19(6):758-63. PubMed ID: 15665624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells.
    Slingluff CL; Petroni GR; Yamshchikov GV; Barnd DL; Eastham S; Galavotti H; Patterson JW; Deacon DH; Hibbitts S; Teates D; Neese PY; Grosh WW; Chianese-Bullock KA; Woodson EM; Wiernasz CJ; Merrill P; Gibson J; Ross M; Engelhard VH
    J Clin Oncol; 2003 Nov; 21(21):4016-26. PubMed ID: 14581425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients.
    Luiten RM; Kueter EW; Mooi W; Gallee MP; Rankin EM; Gerritsen WR; Clift SM; Nooijen WJ; Weder P; van de Kasteele WF; Sein J; van den Berk PC; Nieweg OE; Berns AM; Spits H; de Gast GC
    J Clin Oncol; 2005 Dec; 23(35):8978-91. PubMed ID: 16260696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity in humans of a transdermal multipeptide melanoma vaccine administered with or without a TLR7 agonist.
    Meneveau MO; Petroni GR; Salerno EP; Lynch KT; Smolkin M; Woodson E; Chianese-Bullock KA; Olson WC; Deacon D; Patterson JW; Grosh WW; Slingluff CL
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34035112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors.
    Di Pucchio T; Pilla L; Capone I; Ferrantini M; Montefiore E; Urbani F; Patuzzo R; Pennacchioli E; Santinami M; Cova A; Sovena G; Arienti F; Lombardo C; Lombardi A; Caporaso P; D'Atri S; Marchetti P; Bonmassar E; Parmiani G; Belardelli F; Rivoltini L
    Cancer Res; 2006 May; 66(9):4943-51. PubMed ID: 16651452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697).
    Butterfield LH; Zhao F; Lee S; Tarhini AA; Margolin KA; White RL; Atkins MB; Cohen GI; Whiteside TL; Kirkwood JM; Lawson DH
    Clin Cancer Res; 2017 Sep; 23(17):5034-5043. PubMed ID: 28536308
    [No Abstract]   [Full Text] [Related]  

  • 14. Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma.
    Perales MA; Yuan J; Powel S; Gallardo HF; Rasalan TS; Gonzalez C; Manukian G; Wang J; Zhang Y; Chapman PB; Krown SE; Livingston PO; Ejadi S; Panageas KS; Engelhorn ME; Terzulli SL; Houghton AN; Wolchok JD
    Mol Ther; 2008 Dec; 16(12):2022-9. PubMed ID: 18797450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma.
    Chianese-Bullock KA; Pressley J; Garbee C; Hibbitts S; Murphy C; Yamshchikov G; Petroni GR; Bissonette EA; Neese PY; Grosh WW; Merrill P; Fink R; Woodson EM; Wiernasz CJ; Patterson JW; Slingluff CL
    J Immunol; 2005 Mar; 174(5):3080-6. PubMed ID: 15728523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma.
    Scheibenbogen C; Schmittel A; Keilholz U; Allgäuer T; Hofmann U; Max R; Thiel E; Schadendorf D
    J Immunother; 2000; 23(2):275-81. PubMed ID: 10746554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-α or TLR-9 agonist and GM-CSF with peptide vaccination.
    Tarhini AA; Butterfield LH; Shuai Y; Gooding WE; Kalinski P; Kirkwood JM
    J Immunother; 2012; 35(9):702-10. PubMed ID: 23090079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial.
    Slingluff CL; Petroni GR; Olson WC; Smolkin ME; Ross MI; Haas NB; Grosh WW; Boisvert ME; Kirkwood JM; Chianese-Bullock KA
    Clin Cancer Res; 2009 Nov; 15(22):7036-44. PubMed ID: 19903780
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients.
    Pilla L; Patuzzo R; Rivoltini L; Maio M; Pennacchioli E; Lamaj E; Maurichi A; Massarut S; Marchianò A; Santantonio C; Tosi D; Arienti F; Cova A; Sovena G; Piris A; Nonaka D; Bersani I; Di Florio A; Luigi M; Srivastava PK; Hoos A; Santinami M; Parmiani G
    Cancer Immunol Immunother; 2006 Aug; 55(8):958-68. PubMed ID: 16215718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autoimmune toxicities associated with the administration of antitumor vaccines and low-dose interleukin-2.
    Chianese-Bullock KA; Woodson EM; Tao H; Boerner SA; Smolkin M; Grosh WW; Neese PY; Merrill P; Petroni GR; Slingluff CL
    J Immunother; 2005; 28(4):412-9. PubMed ID: 16000961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.